Plain-English translation of NCT07077486 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study compares two different treatment approaches for people with lupus who have developed interstitial lung disease (scarring or inflammation in the lungs). One group will receive telitacicept, a newer biologic medication, combined with standard lupus medications. The other group will receive cyclophosphamide, a chemotherapy drug that is the current standard treatment, also combined with other standard medications. Researchers want to see if the newer medication works as well or better than the traditional approach, with fewer side effects.
Lung problems affect many people with lupus, and some develop serious scarring in their lungs. While cyclophosphamide is the standard treatment, it can cause significant side effects. This medication may offer a gentler option that still controls lung disease effectively, and researchers also want to better understand how lupus damages the lungs so they can identify who will benefit most from treatment.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the newer medication (telitacicept) or the standard cyclophosphamide treatment, along with other lupus medications your doctor thinks you need. You'll receive regular doses of your assigned treatment and attend multiple clinic visits for blood tests, lung function tests, and CT scans to monitor how your lungs are responding. The study involves close follow-up to track whether the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China